OS Therapies to Report Second Quarter 2025 Financial Results and Provide Business Update on Tuesday, August 19th, 2025
OS Therapies (NYSE American: OSTX), a clinical-stage biotechnology company focused on cancer immunotherapy and antibody drug conjugates, has scheduled its second quarter 2025 financial results announcement for Tuesday, August 19, 2025. The company will present its financial performance for the period ended June 30, 2025, along with a business update.
OS Therapies (NYSE American: OSTX), società biotecnologica in fase clinica specializzata in immunoterapia oncologica e coniugati anticorpo-farmaco, ha fissato la pubblicazione dei risultati finanziari del secondo trimestre 2025 per martedì 19 agosto 2025. L’azienda presenterà i dati relativi al periodo chiuso al 30 giugno 2025 e fornirà un aggiornamento sull’attività.
OS Therapies (NYSE American: OSTX), una compañía biotecnológica en fase clínica centrada en inmunoterapia contra el cáncer y conjugados anticuerpo-fármaco, ha programado el anuncio de sus resultados financieros del segundo trimestre de 2025 para martes 19 de agosto de 2025. La empresa dará a conocer sus resultados correspondientes al periodo cerrado el 30 de junio de 2025 y ofrecerá una actualización sobre su negocio.
OS Therapies (NYSE American: OSTX)는 암 면역요법 및 항체-약물 결합체(ADC)를 연구하는 임상 단계의 생명공학 기업으로, 2025년 2분기 재무실적 발표를 2025년 8월 19일 화요일로 예정했습니다. 회사는 2025년 6월 30일로 종료된 기간의 재무성과를 발표하고 사업 현황을 업데이트할 예정입니다.
OS Therapies (NYSE American: OSTX), une société biotechnologique en phase clinique spécialisée dans l'immunothérapie anticancéreuse et les conjugués anticorps-médicament, a programmé la publication de ses résultats financiers du deuxième trimestre 2025 pour mardi 19 août 2025. La société présentera les performances pour la période close le 30 juin 2025 et fera le point sur ses activités.
OS Therapies (NYSE American: OSTX), ein biotechnologisches Unternehmen in der klinischen Entwicklungsphase mit Schwerpunkt auf Krebsimmuntherapien und Antikörper-Wirkstoff-Konjugaten, hat die Bekanntgabe der Finanzergebnisse für das zweite Quartal 2025 auf Dienstag, den 19. August 2025 terminiert. Das Unternehmen wird die Ergebnisse für den zum 30. Juni 2025 abgeschlossenen Zeitraum vorstellen und ein Geschäftsupdate geben.
- None.
- None.
New York, New York--(Newsfile Corp. - August 14, 2025) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today announced that it will report second quarter 2025 financial results ended June 30, 2025 and provide a business update on the morning of Tuesday, August 19, 2025.
About OS Therapies
OS Therapies is a clinical stage oncology company focused on the identification, development, and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. OST-HER2, the Company's lead asset, is an immunotherapy leveraging the immune-stimulatory effects of Listeria bacteria to initiate a strong immune response targeting the HER2 protein. OST-HER2 has received Rare Pediatric Disease Designation (RPDD) from the U.S. Food & Drug Administration and Fast-Track and Orphan Drug designations from the U.S. FDA and European Medicines Agency. The Company reported positive data in its Phase 2b clinical trial of OST-HER2 in recurrent, fully resected, lung metastatic osteosarcoma, demonstrating statistically significant benefit in the 12-month event free survival (EFS) primary endpoint of the study. The Company anticipates submitting a Biologics Licensing Application (BLA) to the U.S. FDA for OST-HER2 in osteosarcoma in 2025 and, if approved, would become eligible to receive a Priority Review Voucher that it could then sell. OST-HER2 has completed a Phase 1 clinical study primarily in breast cancer patients, in addition to showing preclinical efficacy data in various models of breast cancer. OST-HER2 has been conditionally approved by the U.S. Department of Agriculture for the treatment of canines with osteosarcoma.
In addition, OS Therapies is advancing its next-generation Antibody Drug Conjugate (ADC) and Drug Conjugates (DC), known as tunable ADC (tADC), which features tunable, tailored antibody-linker-payload candidates. This platform leverages the Company's proprietary silicone Si-Linker and Conditionally Active Payload (CAP) technology, enabling the delivery of multiple payloads per linker. For more information, please visit www.ostherapies.com.
Forward-Looking Statements
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute forward-looking statements within the meaning of the federal securities laws. These forward-looking statements and terms such as "anticipate," "expect," "intend," "may," "will," "should" or other comparable terms involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Those statements include statements regarding the intent, belief or current expectations of OS Therapies and members of its management, as well as the assumptions on which such statements are based. OS Therapies cautions readers that forward-looking statements are based on management's expectations and assumptions as of the date of this press release and are subject to certain risks and uncertainties that could cause actual results to differ materially, including, but not limited to the risks and uncertainties described in "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's most recent Annual Report on Form 10-K, most recent Quarterly Report on Form 10-Q and other subsequent documents the Company files with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and, except as required by the federal securities laws, OS Therapies specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
OS Therapies Contact Information:
Investor Relations
Harrison Seidner, PhD
WaterSeid Partners
OSTX@waterseid.com
Public Relations
Stephanie Chen
Elev8 New Media
stephanie@elev8newmedia.com
https://x.com/OSTherapies
https://www.instagram.com/ostherapies/
https://www.facebook.com/OSTherapies/
https://www.linkedin.com/company/os-therapies/
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/262600
FAQ
When will OS Therapies (OSTX) release Q2 2025 earnings?
What is OS Therapies' (OSTX) main business focus?
What period will OS Therapies' (OSTX) Q2 2025 financial results cover?
What type of updates will OS Therapies (OSTX) provide in the Q2 2025 announcement?
